New JAMA studies examine whether routine colonoscopies and low‑dose thyroid drugs benefit older adults, raising questions ...
Levothyroxine is one of the most commonly used medicines in the United States. It is mainly prescribed to treat thyroid ...
In some cases, lifelong therapy will be necessary. But many cases of hypothyroidism, especially subclinical hypothyroidism, ...
Did The Thyroid Pill Become a Habit? Levothyroxine, the preferred treatment for hypothyroidism, is one of the most prescribed medications worldwide, mostly initiated in adults age ...
To address this, researchers conducted a prospective, single-group study in community-dwelling adults aged 60 years and older who had been on a stable levothyroxine dose (≤150 g ...
About one-quarter of adults aged at least 60 years using levothyroxine were able to stop therapy and maintain a thyroid-stimulating hormone level of less than 10 mIU/L at 1 year, researchers reported ...
Experts call for better guidance on levothyroxine initiation, deprescribing ...
The U.S. Food and Drug Administration announced on Thursday its approval of a new, higher-dose Wegovy (semaglutide) injection. The 7.2 mg dosage, called Wegovy HD, is intended for weight loss and long ...
A paper presenting three clinical case studies helps to explain levothyroxine overprescription -- and how and why it can be deprescribed. "Once levothyroxine is initiated, it is continued lifelong for ...
The FDA has approved a higher 7.2 mg dose of Novo Nordisk’s Wegovy (Wegovy HD) for chronic weight management in adults with obesity. The new dose showed greater weight loss in a large clinical trial ...
The Food and Drug Administration (FDA) on Thursday approved a higher dose of the Wegovy weight loss drug. The manufacturer, Novo Nordisk, increased the semaglutide injection by 4.8 mg to total 7.2 mg.
Novo Nordisk NOVO.B1.07%increase; green up pointing triangle said the U.S. Food and Drug Administration approved a higher dosage of its Wegovy weight-loss medication, a boost for the Danish drugmaker ...